China-based Ascletis Pharma Inc. (HKG: 1672) announced that it has filed an Investigational New Drug (IND) application for ASC10, an oral RNA-dependent RNA polymerase (RdRp) inhibitor being developed to treat COVID-19, with the US FDA following a pre-IND consultation.
Drug Profile
ASC10 is an orally bioavailable, double prodrug of the antiviral nucleoside analog ASC10-A, which has demonstrated a potent inhibitory effect against RdRp of the SARS-CoV-2 virus. ASC10-A has shown excellent in vitro antiviral activity against multiple SARS-CoV-2 virus variants, including Omicron, in preclinical studies.-Fineline Info & Tech
